Sweden-based Elekta has signed a $29m agreement to deliver several of its Versa HD linear accelerators as well as software support and services to The Ottawa Hospital (TOH) in Ontario, Canada.
The agreement is for a period of more than eight years. Elekta has scheduled the initial Versa HD deliveries for this year.
The Ottawa Hospital Radiation Oncology head Dr Jason Pantarotto said: “Elekta’s Versa HD linear accelerators will enable us to treat a broad spectrum of tumours throughout the body.
“The advanced technology will help us increase the use of high dose radiation treatments such as stereotactic body radiotherapy. These treatments reduce the total number of patient visits while improving clinical effectiveness.”
Claimed to be the high-versatility treatment system, Versa HD gives clinicians the flexibility to deliver conventional therapies to treat several small as well as large tumours throughout the body.
Highly complex cancers that require extreme targeting precision can also be treated using the system.
Elekta North America executive vice-president Pete Gaccione said: “We share The Ottawa Hospital’s vision to provide each patient with the world-class care. This agreement will provide thousands of patients at the hospital the opportunity to receive advanced cancer care.”
Every year, more than 85,000 people are diagnosed with cancer in Ontario.
